Yasmine Assadipour1, Hui Zhou2, Eric J Kuo3, Philip I Haigh4, Annette L Adams2, Michael W Yeh3. 1. Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA. Electronic address: ya@vasurgery.com. 2. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. 3. Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA. 4. Department of Surgery, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA.
Abstract
BACKGROUND: Patients with primary hyperparathyroidism are at risk for skeletal and renal end-organ damage. METHODS: We studied patients with biochemically confirmed primary hyperparathyroidism from 1995-2014 and quantified the frequency of osteoporosis, nephrolithiasis, hypercalciuria, and decrease in renal function. RESULTS: The cohort comprised 9,485 patients. In total, 3,303 (35%) had preexisting end-organ effects (osteoporosis, 24%; nephrolithiasis, 10%; hypercalciuria, 5%). Of 6,182 remaining patients, 1,769 (29%) exhibited progression to 1 or more end-organ effects over a median 3.7 years. Among patients with classic primary hyperparathyroidism (calcium and parathyroid hormone increased), progression was unrelated to the degree of hypercalcemia (calcium >11.5 mg/dL, hazard ratio 1.03, 95% confidence interval 0.85-1.25; 11.1-11.5 mg/dL, HR 1.07, 95% confidence interval 0.93-1.23; 10.5-11.0 mg/dL = reference). Patients with nonclassic primary hyperparathyroidism (calcium increased, parathyroid hormone 40-65 pg/mL) had a lesser risk of progression (calcium >11.5 mg/dL, hazard ratio 0.68, 95% confidence interval 0.50-0.94; 11.1-11.5 mg/dL, hazard ratio 0.68, 95% confidence interval 0.56-0.82; 10.5-11.0 mg/dL, hazard ratio 0.66, 95% confidence interval 0.59-0.74). End-organ damage developed before or within 5 years of diagnosis for 62% of patients. CONCLUSION: End-organ manifestations of primary hyperparathyroidism develop before biochemical diagnosis or within 5 years in most patients. End-organ damage occurred more frequently in patients with classic primary hyperparathyroidism versus nonclassic primary hyperparathyroidism, regardless of severity of hypercalcemia.
BACKGROUND:Patients with primary hyperparathyroidism are at risk for skeletal and renal end-organ damage. METHODS: We studied patients with biochemically confirmed primary hyperparathyroidism from 1995-2014 and quantified the frequency of osteoporosis, nephrolithiasis, hypercalciuria, and decrease in renal function. RESULTS: The cohort comprised 9,485 patients. In total, 3,303 (35%) had preexisting end-organ effects (osteoporosis, 24%; nephrolithiasis, 10%; hypercalciuria, 5%). Of 6,182 remaining patients, 1,769 (29%) exhibited progression to 1 or more end-organ effects over a median 3.7 years. Among patients with classic primary hyperparathyroidism (calcium and parathyroid hormone increased), progression was unrelated to the degree of hypercalcemia (calcium >11.5 mg/dL, hazard ratio 1.03, 95% confidence interval 0.85-1.25; 11.1-11.5 mg/dL, HR 1.07, 95% confidence interval 0.93-1.23; 10.5-11.0 mg/dL = reference). Patients with nonclassic primary hyperparathyroidism (calcium increased, parathyroid hormone 40-65 pg/mL) had a lesser risk of progression (calcium >11.5 mg/dL, hazard ratio 0.68, 95% confidence interval 0.50-0.94; 11.1-11.5 mg/dL, hazard ratio 0.68, 95% confidence interval 0.56-0.82; 10.5-11.0 mg/dL, hazard ratio 0.66, 95% confidence interval 0.59-0.74). End-organ damage developed before or within 5 years of diagnosis for 62% of patients. CONCLUSION: End-organ manifestations of primary hyperparathyroidism develop before biochemical diagnosis or within 5 years in most patients. End-organ damage occurred more frequently in patients with classic primary hyperparathyroidism versus nonclassic primary hyperparathyroidism, regardless of severity of hypercalcemia.
Authors: V Pandzic Jaksic; A Majic; T Rezic; J Andric; O Jaksic; A Zrilic; S Marusic Journal: Acta Endocrinol (Buchar) Date: 2021 Apr-Jun Impact factor: 0.877
Authors: Kristian F Axelsson; Märit Wallander; Helena Johansson; Nicholas C Harvey; Liesbeth Vandenput; Eugene McCloskey; Enwu Liu; John A Kanis; Henrik Litsne; Mattias Lorentzon Journal: JAMA Netw Open Date: 2022-06-01
Authors: Whitney Sutton; Joseph K Canner; Jessica B Shank; Abbey L Fingeret; Shkala Karzai; Dorry L Segev; Jason D Prescott; Aarti Mathur Journal: Am J Surg Date: 2022-03-19 Impact factor: 3.125
Authors: Carolyn D Seib; Tong Meng; Insoo Suh; Robin M Cisco; Dana T Lin; Arden M Morris; Amber W Trickey; Electron Kebebew Journal: Surgery Date: 2020-07-09 Impact factor: 3.982
Authors: Wilson M Alobuia; Tong Meng; Robin M Cisco; Dana T Lin; Insoo Suh; Manjula Kurella Tamura; Amber W Trickey; Electron Kebebew; Carolyn D Seib Journal: Surgery Date: 2021-07-03 Impact factor: 3.982